Top Markets
Coin of the day
PharmAust Limited PharmAust Limited

PharmAust Limited

PAA
Rang in aandelen #26700
Operating internationally, including in Switzerland, Australia, Sweden, and the... Operating internationally, including in Switzerland, Australia, Sweden, and the United States, PharmAust Limited specializes in developing targeted cancer treatments for both human and animal applications. The company also cultivates intellectual property in drug discovery, addressing a range of cancers and neurological conditions. Its primary therapeutic candidate is Monepantel (MPL), a small molecule compound currently undergoing Phase II clinical trials for cancer treatment. Beyond its drug development pipeline, PharmAust provides synthetic and medicinal chemistry products and expert services to the global drug discovery and pharmaceutical sectors. The firm also holds a research agreement with the Walter and Eliza Hall Institute, investigating in vitro the effects of MPL on human T-lymphotrophic virus-1 (HTLV-1) infections. Established in 2000, PharmAust Limited is headquartered in Bentley, Australia.
Aandeelprijs
$0.12164306
Laatst gesynchroniseerd: 2024-11-11
Marktkapitalisatie
$38.53M
Verandering (1 dag)
-4.14%
Verandering (1 jaar)
0.00%
Land
AU
Handel PharmAust Limited (PAA)

Categorie

Winst voor PharmAust Limited (PAA)
Winst in Jun 2024 TTM: $-6.31M
Volgens de meest recente financiële verslagen van PharmAust Limited bedraagt de huidige winst van het bedrijf $-6.31M. In 2023 behaalde het bedrijf een winst van $-4.14M, een daling ten opzichte van de winst van 2022, die $-1.18M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van PharmAust Limited van 2001 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
2026 (TTM) $-6.31M 0.00%
2024 $-6.31M 52.51%
2023 $-4.14M 251.26%
2022 $-1.18M 17.50%
2021 $-1.00M 6.70%
2020 $-939.77K -13.74%
2019 $-1.09M -41.67%
2018 $-1.87M 80.51%
2017 $-1.03M -64.63%
2016 $-2.93M 97.39%
2015 $-1.48M 19.24%
2014 $-1.24M 112.82%
2013 $-584.08K -86.59%
2012 $-4.35M -29.96%
2011 $-6.22M 1,573.65%
2010 $-371.45K 155.62%
2009 $-145.32K -97.37%
2008 $-5.53M -0.89%
2007 $-5.58M 173.13%
2006 $-2.04M -20.13%
2005 $-2.56M 42.56%
2004 $-1.80M 29.13%
2003 $-1.39M -33.40%
2002 $-2.09M 96.03%
2001 $-1.06M 0.00%
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
$5.27B -83,669.91%
US
$1.95B -31,004.03%
NL
$1.61B -25,675.00%
AU
$-3.09B 48,807.15%
US
- -
CH